Overview

Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease

Status:
Unknown status

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

Summary

The primary purposes of this study are to assess the safety and efficacy of using high doses of the drug Icotinib (Conmana) as a way to treat patients with non-small cell lung cancer that achieve stable disease after 8 weeks routine therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Betta Pharmaceuticals Co., Ltd.
Betta Pharmaceuticals Co.,Ltd.